Search

Your search keyword '"A G, Zeimet"' showing total 217 results

Search Constraints

Start Over You searched for: Author "A G, Zeimet" Remove constraint Author: "A G, Zeimet"
217 results on '"A G, Zeimet"'

Search Results

1. BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer

2. The game-changing impact of POLE mutations in oncology—a review from a gynecologic oncology perspective

3. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

4. A comparison of four technologies for detecting p53 aggregates in ovarian cancer

5. Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer

6. Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens

9. Data from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

11. Supplementary Figure 2 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

13. Data from DNA Hypomethylation and Ovarian Cancer Biology

14. Supplementary Figure 3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

15. Supplementary Figure 1 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer

16. Treatment strategies in patients with gynecological sarcoma : Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)

17. Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data

18. Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort

19. PARP inhibitors in the treatment of ovarian cancer

21. The miR-34 family and its clinical significance in ovarian cancer

22. High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome

23. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study

25. Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer

26. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

28. Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory

29. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities

30. Adjuvante Therapie des Endometriumkarzinoms

31. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer

32. Evaluation of Vav3.1 as prognostic marker in endometrial cancer

33. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer

34. Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

35. Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response

36. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours

37. TNFα signalling predicts poor prognosis of patients with endometrial cancer

38. Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens

39. Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer

40. TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial

41. Clinical Impact of RANK Signalling in Ovarian Cancer

42. Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium

43. Abstract 947: Effects of methadone on ovarian cancer cell-lines and patient-derived tumor-spheroids

44. Evaluating L1CAM expression in human endometrial cancer using qRT-PCR

45. Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer

46. Ovarian Cancer Stem Cell Heterogeneity

47. Intraperitoneale Chemotherapie in der Behandlung des Ovarial- und Tubenkarzinoms

48. Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer

49. Immunotherapy in ovarian cancer: fake news or the real deal?

50. (Iso‐)form Matters: Differential Implication of Vav3 Variants in Ovarian Cancer

Catalog

Books, media, physical & digital resources